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The prevalence of growth hormone secreting pituitary tumours in domestic cats (Felis catus) is 
ten times greater than in humans. The predominant inhibitory receptors of growth hormone-
secreting pituitary tumours are somatostatin receptors (SSTRs) and dopamine receptor 2 
(DRD2). The expression of these receptors is associated with the response to somatostatin 
analogue and dopamine agonist treatment in human patients with acromegaly. The aim of this 
study was to describe pathological features of pituitaries from domestic cats with acromegaly, 
pituitary receptor expression and investigate correlates with clinical data including pituitary 
volume, time since diagnosis of diabetes, insulin requirement and serum IGF1 concentration. 
Loss of reticulin structure was identified in 15/21 pituitaries, of which 10/15 exhibited acinar 
hyperplasia. SSTR1, SSTR2, SSTR5 and DRD2 mRNA were identified in the feline pituitary 
while SSTR3 and SSTR4 were not. Expression of SSTR1, SSTR2 and SSTR5 was greater in 
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acromegalic cats compared to controls. A negative correlation was identified between DRD2 
mRNA expression and pituitary volume. The loss of DRD2 expression should be investigated as 
a mechanism allowing the development of larger pituitary tumours.  
3. Introduction 
Acromegaly is typically caused by a functional growth hormone (GH)-secreting pituitary 
adenoma in humans, and results in increased circulating insulin-like growth factor 1 (IGF1) 1. 
Medical management therapies for acromegaly include GH receptor antagonists, dopamine 
receptor agonists (DRA) and somatostatin analogues, with the latter being the medical therapy of 
choice in most cases 2,3. However, 30 to 65 % of patients with acromegaly receiving somatostatin 
analogues for 12 months fail to achieve biochemical disease control 4–6. This limited response to 
therapy is justification for ongoing research to develop therapies which improve outcomes in 
medically managed patients 7.  
Animal models can provide insight into disease pathophysiology and are used for therapeutic 
drug development. Transgenic rats, mice and rabbits are commonly used as induced acromegalic 
models by over-expression of GHRH or aryl hydrocarbon receptor-interacting protein knockout 
8–11
. However, these models do not replicate GH-secreting pituitary adenomas identified in most 
human patients with acromegaly, and this might limit the predictability of pharmacological 
studies of tumorous pituitary GH-secretion inhibition when using them. Additionally, the study 
of a naturally occurring disease from an animal which lives in a similar environment to humans 
would be favourable to account for the potential environmental effects on pituitary dysfunction. 
Spontaneous acromegaly / hypersomatotropism (HST) in domestic cats (Felis catus) is ten 
times more prevalent than in humans, affecting an estimated 1 in 800 cats 12–14. Acromegaly in 
cats parallels the disease in humans in-so-far-as being diagnosed in middle aged to older subjects 
and is associated with insulin resistance, acral growth and cardiovascular complications 12,15. 
Cats affected by acromegaly have achieved long-term clinical and biochemical response to 
pasireotide and cabergoline but no other medical therapies 16–19. The somatostatin and dopamine 
receptor profile of feline GH-secreting adenomas is not known. The receptor expression profile 
of these tumours might explain the poor response of feline acromegalics to octreotide, which has 
high binding affinity for and preferentially binds to SSTR2, and L-deprenyl, a monoamine 
oxidase B inhibitor which prolongs the activity of dopamine, but favourable response to 
pasireotide treatment 16,20,21.  
The aim of the study was to investigate whether cats with naturally occurring acromegaly are 
a suitable model for the human disease, as well as a species of interest from a veterinary 
perspective. The study aimed to describe the pituitary pathological findings, hormone, 
somatostatin and dopamine receptor expression of cats with and without acromegaly. 
Additionally, the receptor expression data were compared to clinical data. 
4. Materials and Methods 
The study was approved by the Royal Veterinary College (RVC) Ethics and Welfare Committee 
(URN 2014 1306). 
Animals 
Written informed consent was obtained from owners of all enrolled cats. Cats had a diagnosis of 
acromegaly on the basis of appropriate clinical history, serum IGF1 concentration > 1000 ng/mL 
(reference interval 200 – 700 ng/mL) which has a 95% positive predictive value for acromegaly 
12
, and pituitary enlargement diagnosed using intra-cranial imaging (contrast enhanced computed 
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tomography) or post-mortem examination 12. All acromegalic cats had concurrent diabetes 
mellitus which was likely to be secondary to acromegaly, and were receiving lente insulin 
(Caninsulin, MSD Animal Health), protamine zinc insulin (Prozinc, Boehringer Ingelheim) or 
glargine insulin (Lantus, Sanofi) (HST group). Non-acromegalic cats who did not have a clinical 
history consistent with acromegaly nor pituitary enlargement, but had undergone post-mortem 
examination and whose owners consented to be enrolled in the study were consecutively 
recruited. All cats had previously been patients of the Queen Mother Hospital for Animals, RVC, 
Beaumont Animals’ Hospital, RVC or People’s Dispensary for Sick Animals in London, UK. All 
cats had been neutered which is common in the UK for patient health and population control. 
Cat pituitary tissue  
Pituitary tissue was obtained at the time of post-mortem examination or therapeutic 
hypophysectomy. Tissue was fixed in RNAlaterTM (Sigma-Aldrich, Dorset, UK) or snap frozen 
in liquid nitrogen and stored at - 80 oC until processed in batches. A section of pituitary tissue 
was also fixed in 10% w/v neutral buffered formalin, dehydrated in decreasing concentrations of 
ethanol then embedded into paraffin blocks and stored at room temperature (RT). A summary of 
clinical characteristics of the enrolled cats is presented in Table 1. 
Reticulin staining 
Tissue sections were cut, deparaffinised and rehydrated as follows: 4 µm sections were cut using 
a manual rotary microtome (Leica RM2235, Leica Biosystems Ltd., Newcastle upon Tyne, UK) 
and air dried onto microscope slides (SuperfrostTM Microscope Slides, Thermo Fisher Scientific); 
deparaffinisation of the sections was performed by heating slides to 60 oC for 5 min followed by 
2 x 5 min immersion in HistoClear (National Diagnostics, Atlanta, GA, USA) or xylene (Sigma-
Aldrich) and rehydration of tissues in decreasing concentrations of ethanol. A commercially 
available reticulin staining kit (Reticulin Stain ab150684, Abcam, Cambridge, UK) was used, 
and the procedure performed as per manufacturer guidelines apart from use of 1 M ammonium 
hydroxide where the kit describes use of ‘concentrated ammonium hydroxide’ to make the 
‘working ammoniacal silver solution’. A feline kidney tissue section was used as a positive 
control for each batch of reticulin fibre staining.  
Ten control pituitary samples were used to develop a reference interval for the number of 
nuclei within each acinus and area of each acinus. Ten acini from each sample were randomly 
selected from each pituitary. This resulted in 100 acini being used for reference interval 
determination. This reference interval was then tested using two other control pituitary samples. 
Three assessors (Dr Christopher Scudder (CJS), Ms Katarina Hazuchova [KH] Veterinary 
Internal Medicine Specialist and Ms Norelene Harrington [NH] Specialist in Veterinary 
Pathology) were used to determine whether pituitary acinar morphology was altered in pituitaries 
from cats with acromegaly. Each assessor was asked the following questions: Is the acinar 
structure altered?; Are the acini increased in size?; Is there loss of acinus structure?; Is the 
distribution focal, multi-focal or diffuse? Loss of acinus structure would be consistent with 
adenomatous change and an increased size of acini would be consistent with acinar hyperplasia. 
The upper reference limit for acinar size is described in ‘Reticulin staining’ results and the 
response to the above questions was used to determine a consensus between assessors. 
Immunohistochemistry 
All pituitary samples used for immunohistochemistry had previously undergone haematoxylin 
and eosin staining. Pituitary tissue embedded in paraffin blocks was cut into 4 µm sections and 
air dried on positively charged slides (SuperfrostTM Plus Microscope Slides, Thermo Fisher 
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Scientific, Loughborough, UK). Immunohistochemistry was performed as previously described 
22
 by deparaffinisation and rehydration of the sections as per reticulin staining. Antigen retrieval 
for GH immunostaining was not necessary. Antigen retrieval for PRL and SSTR2 quantification 
and was required. For PRL immunostaining, slides were immersed in a pH 9.0 Tris- 
Ethylenediaminetetraacetic acid (EDTA) Buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% 
Tween 20), followed by microwave heating at 650 W for 4 min x 4. For SSTR2 immunostaining, 
slides were immersed in 10 mM citrate buffer pH 6 and microwave heating at 650 W for 4 min x 
4. Slides were cooled to RT over 30 minutes followed by blocking of endogenous peroxidase by 
immersion in 3 % v/v H2O2 for 10 min. Non-specific protein binding was blocked by immersion 
in a buffer containing PBS (Gibco, ThermoFisher Scientific, Loughborough, UK), 5 % goat 
serum (Sigma-Aldrich, Dorset, UK), 1 % BSA (Sigma-Aldrich, Dorset, UK), 0.1 % w/v Triton™ 
X-100 (Sigma-Aldrich, Dorset, UK) and 0.05 % Tween® 20 (ThermoFisher Scientific, 
Loughborough, UK). 
Primary antibody incubation was performed overnight in a cold room.  Rabbit anti-porcine 
GH and rabbit anti-porcine PRL antibodies were used 23,24. The primary antibodies were 
delivered lyophilised and reconstituted using PBS to a concentration of 1 mg/mL for anti-porcine 
GH antibody and 300 µg/mL for anti-porcine PRL antibody as per manufacturers guidelines. 
Primary antibody incubation using anti-porcine GH at 1:6000 dilution, anti-porcine PRL at 
1:4000 dilution and anti-SSTR2 25 at 1:1600 dilution. Secondary antibody incubation was 
performed using species-specific biotinylated antibodies (Vector Laboratories, Peterborough, 
UK) for 30 mins at RT followed by incubation with Avidin / Biotin Complex (Vector 
Laboratories, Peterborough, UK) for 30 mins at RT. Slides were then incubated with DAB 
chromogen (Vector Laboratories, Peterborough, UK) for 2 min, followed by counterstaining 
using Gill’s Haematoxylin for 40 s at RT. Between each step the slides were washed in PBS and 
0.05 % Tween 20 for 5 min x 3. Tissues were dehydrated in increasing concentrations of ethanol 
then slides were cover slipped using Vectashield Antifade Mounting Medium (Vector 
Laboratories, Peterborough, UK) and analysed. Negative control samples underwent 
immunohistochemistry as described above but without addition of the primary antibody and 
positive control samples were sections from a healthy mouse pituitary for GH and PRL, and from 
a healthy human pituitary for SSTR2 immunostaining. 
Representative immunostaining for GH and PRL are presented in Figure 1. The percentage 
DAB immunoreactivity of each tissue section was determined by obtaining high resolution 
photomicrographs at x100 magnification (Leica DM4000 B, Leica Microsystems Ltd, Milton 
Keynes, UK) and stitching images from each tissue together using photo editing software 
(Microsoft Image Composite Editor 2.0 for Windows, Redmond, WA, USA) to create a digital 
copy of the tissue. Area measurements were performed using Volocity version 6.3.0 (Perkin 
Elmer, Waltham, MA, USA). The area of DAB labelling was detected by thresholding of hue 
and saturation. Any contiguous object smaller than five pixels was considered noise and 
excluded before the total area of the detected object was calculated. The total tissue area was also 
detected and used to calculate percentage DAB positivity of each tissue. Scoring of sections 
which used anti-SSTR2 antibodies as the primary antibody was also performed by three 
individuals in a blinded manner using a semi quantitative scale as previously described 26. 
Immunoreactivity intensity was graded 0 to 3 (0 = absent; 1 = cytoplasmic staining; 2 = 
membranous staining in less than 50 % cells or incomplete membranous staining; and 3 = 
circumferential membranous staining in >5 % cells, see Figure 2 for examples). If there was a 
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conflict of the pituitary score between one reviewer but two agreed then the agreed score was 
used, and if all three reviewers disagreed then the average score was used.  
Pituitary RNA extraction, analysis and selection of reference genes  
Pituitary RNA was extracted from 10 cats without pituitary disease using the phenol chloroform 
technique. The RNA pellet was re-suspended in RNase free water and underwent on-column 
DNase treatment using a commercially available kit and following manufacturer’s instructions 
(RNeasy Maxi Kit, Qiagen, Manchester, UK). RNA quantity and integrity was assessed using 
the Nanodrop™ 1000 Spectrophotometer (Thermo Fisher Scientific, Hemel Hempstead, UK) 
and Agilent 2100 Bioanalyzer (Agilent Biotechnologies, Craven Arms, UK). 
An aliquot of 100 ng of total pituitary RNA was used to synthesise first-strand cDNA using 1 
µl Oligo dTprimer (Promega, Madison, WI, USA) and ImProm-IITM Reverse Transcription 
System (Promega, Madison, WI, USA) per the manufacturer’s instructions with added 
magnesium chloride (Bioline 50mM MgCl2, London, UK). The cDNA was eluted using 100 µl 
of RNase free water and stored at -20 C until batch use. A non-reverse transcribed (nRT) sample 
was prepared as a control for each sample. The selection of the reference genes for GeXP 
multiplex was performed using the geNorm algorithm 27 and feline geNorm 6 gene kit for use 
with SYBR green (Primerdesign, Southampton, UK). An m value of < 0.5 was the cut off for 
selection. RPL18 and SDHA were chosen as the reference genes.  
Multiplex RT-qPCR  
Three custom designed GeXP multiplexes (Beckman Coulter GenomeLab Gene Expression 
Profiler, Wycombe, UK) were used to quantify gene expression. Multiplex 1 consisted of 
primers designed for AIP, CGA, FSHβ, GHRHR, LHβ, PRL, POU1F1, TSHβ, RPL18 and SDHA, 
multiplex 2 consistent of primers designs for POMC, GH1, RPL18 and SDHA and multiplex 3 
consisted of primers for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, DRD2, RPL18 and SDHA28. 
There were two primer sets for the measurement of PRL, labelled as PRLa and PRLb to 
investigate the precision of gene amplification using the GeXP technique. The GeXP multiplex 
was performed as previously described and in accordance with manufacturer’s instructions 29,30. 
This procedure uses the GeXP Start-up Kit (Beckman Coulter, Wycombe, UK) to synthesise 
cDNA using gene specific anti-sense primers with a 3’ universal tag reverse sequence and 100 
ng total pituitary RNA using a G-Storm GS1 thermal cycler and the following protocol; 48 oC, 1 
min, 42 oC, 60 mins, and 95 oC, 5 mins. Following first-strand cDNA synthesis, an aliquot from 
each reaction was added to a PCR master mix containing GenomeLab kit PCR master mix and 
DNA polymerase (Thermo-Start DNA Polymerase, Thermo Fisher Scientific Loughborough, 
UK). PCR reaction was performed using G-Storm GS1 thermal cycler and the following 
protocol; 95 oC for 10 mins, followed by 35 cycles of 94 oC for 30 secs, 55 oC for 30 secs for 
multiplex 1 and 3 and 65 oC for multiplex 2, and 70 oC for 60 secs. Products were analysed by 
separation using capillary electrophoresis followed by fluorescence spectrophotometry and 
quantified using CEQTM 8000 Genetic Analysis System, and GenomeLab Fragment Analysis 
software (Beckman Coulter, Wycombe, UK). Examples of electropherograms for multiplex 1 
and 3 are presented in Figure 3. Due to many samples having SDHA and POMC expression 
below the level of detection, RPL18 was used as the sole reference gene and the difference 
between groups of POMC expression was not undertaken.   
Statistical analysis 
Data was visually assessed for normal distribution using histograms and by performing Shapiro-
Wilk tests. Normally distributed data are described as mean and standard deviation (S.D.) and 
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non-normally distributed data as median and interquartile range (IQR). Statistical significance 
was determined using an unpaired t-tests and Mann Whitney tests. Spearman’s rank or Pearson’s 
correlation was used to test the association between gene expression and clinical variables. 
Agreement of SSTR2 scores between observers was assessed using a two-way random effects 
single measures intra-class correlation coefficient for absolute agreement model. A chi squared 
test was used to test the SSTR2 scores between acromegalic and control groups. A value of P < 
0.05 was considered significant and Holm-Bonferroni adjustment was used for adjustment of 
multiple comparisons where appropriate. Statistical software analyses were performed using 
GraphPad Prism version 7.02 for Windows (GraphPad Software, CA, USA) and IBM SPSS 
Statistics for Windows version 22 (IBM Corp., NY, USA).  
5.Results 
Reticulin staining 
The reticulin staining in the control pituitary glands demonstrated an acinar and cords pattern 
(Figure 4). This pattern is the same as described in the healthy human pituitary gland 31. The 
upper reference interval for the number of nuclei per acinus in the control pituitary samples was 
66, and the upper reference interval for the area of each acinus was 12650 µm2. The two-
remaining control pituitary samples were assessed using this scoring system and both were 
considered within normal limits. A spectrum of altered reticulin staining was identified in the 
HST pituitary samples including enlargement of acini, disrupted reticulin staining and loss of 
reticulin staining (Figure 5). Compression of the normal pituitary parenchyma adjacent to 
neoplastic tissue was also identified which created a ring of cords of reticulin staining in some 
tissue samples. Three assessors reported 7/21 pituitaries exhibited loss of acinus structure, which 
was described as diffuse or multifocal in all cases. Of the remaining pituitaries, two assessors 
(CS and KH for all 8 cases) described as loss of acinus structure in 8/14 cases, which was focal 
in 4/8 and multifocal or diffuse in the remaining 4/8. All three assessors described an increased 
in size of acini in 5/21 pituitaries. Of the remaining pituitaries, two assessors (KH and NH for all 
five pituitaries) described 5/16 pituitaries as having enlarged acini. There were no distinguishing 
clinical features of the 10 cats who were described to exhibit pituitary acinar enlargement 
(acromegaly cat numbers 7, 14, 22, 24, 25, 32, 34, 35, 36 and 38).  
GH and PRL expression  
There was no difference of patient gender (chi squared P = 0.334) or patient age (median control 
vs HST was 11 vs 11 years, Mann-Whitney U test, P = 0.870) between groups but there a 
difference in body weight (median control vs HST was 4.3kg vs 5.4kg, Mann-Whitney U test, P 
= 0.006). The difference in body weight between groups was expected and likely due to the 
acromegalic state.  
There was significantly greater GH protein expression in the HST compared to control group 
(mean 50 ± 27 vs 30 ± 21 %, t(51) = 2.914, P = 0.005), Table 2. Although gene expression of 
GH1 was greater in cats with acromegaly than controls, this was not statistically significant 
(median control vs HST was 3.1 vs 6.2, Mann-Whitney U test, P = 0.071). There was no 
difference of PRL protein or gene expression between the HST and control group (median 
protein expression 1.5 % IQR 10.9 vs 4.1 % IQR 4.2, Mann-Whitney U test P = 0.122 and 
median relative gene expression 2.099 IQR 1.7 vs 2.196 IQR 0.73, Mann-Whitney U test P = 
0.033). There was no correlation between patient age and GH or PRL expression, nor was there 
an association between age and any pituitary gene expression in this study. 
SSTR2 expression  
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The was no difference of patient gender (chi squared P = 0.150), age (mean controls vs HST 10.5 
± 5.9 vs 11 ± 3, t(34) = 0.392 , P = 0.687) but there was a difference of body weight between 
groups (median control vs HST was 4.1 vs 5.5 kg, P = 0.004). 
There was agreement between observers for tissue SSTR2 scores (intra-class correlation 
0.57, 95 % confidence intervals 0.34 – 0.73, P < 0.001). Due to the low number of tissues having 
scores of 0 and 3, groups 0 -1 and 2 -3 were grouped together. There was no difference of 
proportions of SSTR2 scores between acromegalic and control groups. The tissue percentage 
DAB positivity results are shown in Table 2. The percentage DAB positive tissue for SSTR2 
immunoreactivity was greater in the acromegalic group than controls (0.20 % vs 0.016 %, P = 
0.026). Nine samples had both SSTR2 expression data and SSTR2 immunohistochemistry data. 
A positive correlation between SSTR2 gene expression and percentage tissue DAB staining was 
detected (r2 = 0.76, P < 0.001).  
Expression of remaining anterior pituitary hormone and regulatory receptor genes 
Five cats with HST had previously received pasireotide treatment. There was no difference of 
any gene expression data in pasireotide treated and untreated cats, therefore pasireotide treated 
patients were not excluded. There were no differences between gender or ages of patients 
between groups for expression data of CGA, GH1, FSHβ, PRL, TSHβ, DRD2, SSTR1, SSTR2 and 
SSTR5. 
Expression of FSHβ, PRL and TSHβ was detected in all pituitaries (Table 2). Expression of 
CGA was not detected in one control pituitary and LHβ expression was not detected in one 
control and four HST pituitaries. There were no significant differences of hormone expression 
between control and HST pituitaries. In the HST group, there were strong correlations of gene 
expression between the following hormones after adjustment of the P value for multiple testing: 
CGA and FSHβ, CGA and TSHβ, FSHβ and TSHβ and moderate correlation between PRL and 
TSHβ (Table 3).  
The results of the expression of the SSTR1, SSTR2, SSTR5 and DRD2 for individuals with 
HST are in Figure 6. The expression of SSTR3 or SSTR4 was not detected. All remaining 
receptors were detected in 14/19 of the HST group with SSTR5 and DRD2 detected in all the 
HST group. There was significantly greater expression of SSTR1, SSTR2 and SSTR5 in the HST 
group compared to controls (0.093 vs 0.008, Mann-Whitney P = 0.007; 0.036 vs 0.002, t[25]= -
3.34, P < 0.001; 0.151 vs 0.034, Mann Whitney P = 0.004; respectively) (Figure 3A). There was 
highly variable inter- and intra-patient expression of SSTR1, SSTR2 and SSTR5 mRNA in control 
and HST cats; there was moderate correlation between SSTR1 and SSTR5 expression in the HST 
group (Spearman’s rho 0.65, P = 0.005); in the control group this correlation was not statically 
significant (Spearman’s rho 0.71, P = 0.18). No other receptor expression was correlated with 
one another. There was a moderate negative correlation between DRD2 expression and pituitary 
volume within the HST group (Spearman’s rho -0.52, P = 0.041). There was no association 
between somatostatin receptor expression and IGF1 reduction due to pasireotide treatment in the 
cats which had received pasireotide prior to pituitary tissue collection. There was also no 
association between somatostatin receptor expression and insulin dose or length of time 
receiving exogenous insulin therapy. 
6. Discussion 
Human and feline acromegaly share many clinical commonalities and the disease appears to be 
increasing in prevalence in both populations. This might in part be due to increased clinical 
awareness and improved diagnostic tests. This study describes reticulin staining patterns, 
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hormone and regulatory receptor expression in the normal and acromegalic feline pituitary for 
the first time. A description of the normal feline pituitary gland was required because of the 
paucity of current available information. 
The percentage of GH and PRL positive cells in the normal cat pituitary was lower than 
reported in adult humans (28 vs 45 % and 4 vs 15 to 25 % respectively) 32,33. As predominant cell 
type of acidophils are GH-secreting cells, the distribution of acidophils within a H&E stained 
anterior pituitary section largely reflects the distribution of the GH-producing cells within the 
feline pituitary gland in health. 
There was no consistent pattern of distribution of GH-producing cells in the normal feline 
pituitary. These cells were seen to cluster or be evenly distributed throughout the anterior 
pituitary. This pattern differs to the human pituitary where somatotrophs are predominantly 
located within the lateral wings 33. PRL-producing cells tended to form clusters of up to 20 cells. 
This pattern differs to the distribution in humans where they typically occur singularly. However, 
in concordance to humans there was no specific location within the gland the PRL-producing 
cells were seen 32 
Mixed GH- and PRL- adenomas or mammosomatotroph adenomas account for up to 30 % of 
cases of acromegaly in humans 34,35. PRL positive cells accounted for less than 10 % of positive 
cells in 87 % of the acromegalic pituitaries with the remaining samples containing 10.5 %, 10.5 
%, 16 % and 20.5 % of PRL positive cells. Therefore, mixed GH- and PRL-adenomas / 
mammosomatotroph adenomas were not a predominant feature of acromegaly in these cats. 
The prevalence of pituitary hyperplasia was greater than anticipated. It has been proposed 
that hyperplastic change can precede adenomatous transformation in human patients, and 
somatotroph hyperplasia has been shown to result in somatotroph adenoma formation in GHRH-
overexpressing mice 10,36,37. Somatotroph hyperplasia is considered a rare cause of acromegaly in 
humans 38. The prevalence of pituitary hyperplasia might be greater than suggested by these 
results if the progression from hyperplasia to adenoma occurs in cats and the hyperplasia stage is 
missed because many cats are not diagnosed until the onset of DM.  
Cats expressed SSTR1, SSTR2 and SSTR5 while SSTR3 and SSTR4 proved undetectable using 
the employed methodology. Expression of DRD2 was identified in all feline pituitaries. Cats 
displayed a similar pituitary SSTR and DRD2 profile to humans. These data provide therapeutic 
targets for the management of acromegaly in cats and substantiates the comparative potential of 
studying the acromegalic cat as a spontaneously occurring model of the human disease 12. 
Previous reports of SSTR mRNA expression in GH-secreting pituitary adenomas in humans 
describe SSTR5 > SSTR2 while SSTR1 and SSTR3 expression can be highly variable and SSTR4 
expression is absent 39–43. Immunohistochemical reports describe somatotroph receptor 
expression as either SSTR2 > SSTR5 or SSTR5 > SSTR2 44–46. However, these conflicting 
reports might have occurred due to a difference in proportion of sparsely versus densely 
granulated adenomas in the studied groups. These tumour subtypes, which can be differentiated 
by electromicroscopy or CAM5.2 immunoreactivity pattern, have been documented to have 
different somatostatin receptor expression profiles 44,47,48. Protein expression of SSTR2 in cats as 
assessed by immunohistochemistry scoring was lower than reported in humans 44,48. This may be 
a reason for the previously underwhelming response to octreotide in acromegalic cats because 
SSTR2 expression has been positively correlated with octreotide response in humans 18,42,49. 
Only one cat in the acromegalic group exhibited diffuse strong SSTR2 expression which 
suggests certain individual cats might be suitable candidates to receive octreotide to manage their 
acromegaly. The lower SSTR2 expression identified in the cats in this study might be because 
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we did not differentiate between sparsely or densely granulated tumours. Finally, the detected 
positive correlation between SSTR2 gene expression as measured by GeXP multiplex and protein 
levels as measured through immunohistochemistry parallels findings from previous studies, 
further supporting the robustness of this methodology for within gene expression assessment 
48,50
.  
There are several different somatostatin receptor immunostaining scoring systems where 
immunoreactivity is categorised using semi-quantitative systems dependent on pathologist 
description of staining 26,47,51 or percentage cells with staining 44. The current study employed a 
semi-quantitative analyses which assessed subcellular location of staining, and quantification by 
percentage DAB positive tissue. The results of the semi-quantitative analyses revealed the inter-
observer agreement was only fair. Therefore, the percentage DAB positive tissue was used to 
analyse SSTR2 immunoreactivity instead. This type of analysis is only as reliable as the defined 
colour spectrum cut off for presence or absence of staining. The programme for this analysis was 
designed to be highly specific for positively stained tissue. This might have lowered the 
sensitivity for the identification of weakly positively stained tissue and favoured identification of 
the strong membranous staining which was typically more darkly stained than cytoplasmic 
staining. However, the latter could in fact be more appropriate since membranous staining is 
more heavily weighted when scored in many of the semi-quantitative scoring systems; additional 
reassurance was provided by the fact that immunohistochemical analysis data exhibited strong 
correlation with gene expression data.  
The entire acromegalic group expressed DRD2 while DRD2 expression is not found so 
consistently in human samples 46,52,53; PRL expression was also detected in all samples. 
Therefore, the presence of DRD2 might have been due to the presence of lactotrophs. In 
veterinary medicine, acromegalic cats undergo therapeutic total hypophysectomy rather than 
adenomectomy surgery which might result in healthy pituitary tissue being adherent to the 
adenoma. Nevertheless, there was no correlation between PRL expression and DRD2 expression 
which argues against this, and would be consistent with tumorous somatotroph DRD2 
expression. 
There was no difference in DRD2 expression between acromegalic and control cats, although 
a moderate negative correlation between DRD2 expression and pituitary size was detected. 
Dopamine has been shown to block cell cycle progression, and activation of DRD2 by dopamine 
in a gastric cancer cell model has been shown to suppress cancer cell invasion 54,55. Additionally, 
the loss of DRD2 in mice resulted in large prolactinomas 56. DRD2 loss in the pituitary might 
therefore also promote large somatotroph tumour formation in cats. These data also suggest that 
dopamine agonist therapy should be further evaluated in acromegalic cats and particularly in 
those with smaller pituitary tumors, because resistance to dopamine agonist therapy has been 
associated with lower DRD2 expression in human GH-secreting adenomas 53.  
One potential limitation to the study was that all cats with acromegaly were diabetic and 
receiving exogenous insulin. Previous studies in fish have shown SSTR expression to increase in 
a dose dependent manner when exposed to increasing concentrations of insulin and glucose in 
the acute setting 57,58; whether this effect is sustained for longer than 24 hours has not yet been 
reported. Our current studies found no correlations between SSTR expression and insulin dose or 
length of time the cat had been receiving exogenous insulin. Therefore, these findings suggest 
chronic hyperglycaemia or insulin therapy might not affect pituitary somatostatin receptor 
expression in cats.  
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In conclusion, the current study data reveals the heterogeneous expression of SSTRs in the 
pituitary gland from domestic cats without pituitary disease and those with acromegaly. 
Additionally, in parallel with human medicine, DRD2 expression was correlated with pituitary 
tumour size in acromegalic cats. This study has revealed several parallels between humans and 
cats with acromegaly in terms of inhibitory receptor profiles. This receptor characterisation aids 
our understanding of the morphology of the feline pituitary and data suggests acromegalic cats as 
a model of the human disease in terms of developing therapeutics for growth hormone inhibition. 
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Figure 1.Representative photomicrographs of growth hormone (A - C) and prolactin (D – F) 
immunostaining. A and D are x40 photomicrographs demonstrating specific immunostaining for 
somatrophs and lactotrophs, respectively. B and E are photomicrographs from a control cat C 
and F are from an acromegalic cat.  
Figure 2.Representative images of SSTR2 immunoreactivity using feline pituitary tissue. A - D 
represent pituitary tissue exhibiting SSTR2 immunohistochemistry scores 0, 1, 2 and 3, 
respectively using the following criteria:.0 = absent; 1 = cytoplasmic staining; 2 = membranous 
staining in less than 50% cells or incomplete membranous staining; and 3 = circumferential 
membranous staining in >50% cells. All presented photomicrographs collected at x100 
magnification using Leica DM400 B, Leica Microsystems Cambridge, UK. 
Figure 3.An electropherogram results from PCR products using multiplex 1 primer sets The blue 
peaks represent PCR products from gene specific primers and red peaks represent product size 
standards. 
Figure 4.All images stained using Silver stain for reticulin fibres and counter stained using 
Nuclear Fast Red solution. A and C; reconstructed stitched pituitary x100 magnification 
photomicrographs from two control pituitaries. B and D; x400 magnification photomicrographs 
from A and C, respectively. The acinar pattern of reticulin staining is identified in B and D. This 
pattern of reticulin staining was demonstrated in all reticulin staining control pituitaries. 
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Figure 5.All images stained using Silver stain for reticulin fibres and counter stained using 
Nuclear Fast Red solution. A – D; selected images taken from reconstructed stitched pituitary 
x100 magnification photomicrographs from four HST pituitaries. A; disrupted reticulin staining 
and loss of acinar structure. B; areas of enlarged acini (blue stars) and areas of loss of acinar 
structure (blue cross). C; enlarged acini (blue stars) adjacent to normal sized and small acini. D; 
loss of acinar structure in the bottom right of the image (blue stars), and adenomatous tissue has 
compressed the normal pituitary tissue resulting in compression of the acini and a ring of cords 
of acini giving the impression of a pseudocapsule. 
Figure 6.A: Bar charts comparing the relative gene expression of SSTR1, SSTR2 and SSTR5 in 
pituitary tissue from control (CTRL) and acromegalic (Acro) cats determine using GeXP 
multiplex technique. RPL18 is the reference gene. Bar height represents mean and error bars are 
95% confidence intervals ** represents P < 0.01 and *** represents P < 0.001. Dot plot of the 
individual somatostatin profiles from each of the 19 acromegalic cats. 
Table 1.Clinical data of cats in the control and acromegalic groups. All cats enrolled in this study 
were neutered. 
Control 
Group 
Age 
(yrs) 
Sex 1 = 
male 2 = 
female 
Body 
Weight 
(kg) 
Breed Concurrent disease Treatment 
Insulin 
units 
(units / 
q12h) 
Time 
Diabetic 
(m) 
Pituitary 
DV Height 
(mm) 
Pituitary 
Volume 
(cm3) 
IGF1 
(ng/mL) 
1 11 1 3.7 Tonkinese DM insulin - lente 2 5    
2 12 1 5.0 ASH DM insulin - PZI 1.5 16   173 
3 14 1 4.7 DSH DM insullin - PZI 2.5 12   468 
4 10 1 4.4 DSH DM insulin - lente 4.5 1    
5 15 2 3.3 DSH DM insulin - glargine 1 4   222 
6 13 1 5.4 DSH Cardiomyopathy 
furosemide, 
pimobendan, 
clopidogrel      
7 13 2 3.1 DSH Lymphoma 
prednisolone, 
vincristine      
8 15 2 3.4 DLH CKD       
9 1 1 4.6 DSH CKD 
aluminium 
hydroxide      
10 6 1 4.3 Oriental IMHA prednisolone      
11 2 2 4.6 Savannah  Cardiomyopathy none      
12 9 1 6.5 
Norwegian 
Forest Sepsis 
multiple 
antibiotic therapy      
13 7 1  DSH Pleural effusion       
14 15 1 4.7 DSH CKD       
15 16 1 6.6 DSH DM    4  868 
16 8 1 4.0 DSH DM newly diagnosed      
17 2 2 3.5 DSH Myelodysplasia 
prednisolone, 
chlorambucil      
18 16 2 3.1 DSH 
DM / 
Hyperaldosteronism 
insulin - glargine, 
spironolactone  7    
19 12 2 5.2 DSH CKD       
20 1 2 4.1 DSH IMHA 
prednisolone, 
chlorambucil      
21 15 1 4.3 DLH CKD 
aluminium 
hydroxide      
22 18 1 3.9 DSH 
Gastrointestinal 
disease - unclassified       
HST Group 
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1 11 2 6.6 DSH 
DM, chronic 
enteropathy - 
unclassified 
insulin - lente, 
PAS-LAR 2 15 6.2 0.15 1598 
2 11 1 5.7 DSH DM 
insulin - glargine, 
PAS-LAR 2 10 5.0 0.09 >2000 
3 10 1 4.9 DSH 
DM, hepatopathy - 
unclassified insulin - glargine 0.5 15 10.0 0.58 1271 
4 13 1 4.2 DLH DM insulin - lente 7 13 6.6 0.08 1824 
5 14 1 4.1 DSH DM / HCM 
insulin - lente, 
PAS-LAR, 
aspirin 3 53 6.4 0.05 1716 
6 10 1 8.0 DSH DM insulin - glargine 0.5 4 5.0 N/A 1629 
7 13 1 6.5 DSH DM insulin - lente 11 45 7.1 0.13 1885 
8 5 1 7.1 DSH DM insulin - glargine 18 24 5.7 0.09 >2000 
9 10 1 6.0 DSH DM insulin - lente 11 9 7.0 0.14 >2000 
10 6 1 5.0 DLH DM insulin - glargine 3 5 7.8 0.27 1391 
11 15 1 5.0 DSH DM insulin - glargine 4 5 7.0 0.12 1536 
12 14 1 5.4 DSH 
DM, chronic 
enteropathy insulin - glargine 1.5 0 5.8 0.06 1342 
13 11 1 5.2 DSH DM insulin - glargine  0 5.5 0.09 >2000 
14 6 1 7.2 DSH DM insulin - lente  0 4.5 0.07 1289 
15 14 1 4.5 
Maine 
Coon DM insulin - PZI 19 4 6.6 0.08 1847 
16 9 1 4.1 DSH DM insulin - lente 5.5 6 6.1 0.09 1322 
17 14 1 3.5 DSH DM, CKD insulin - lente 7.5 2 0.0 N/A 1395 
18 12 1 5.9 
Maine 
Coon DM insulin - lente 6 4 5.8 0.11 1672 
19 10 1 5.6 DSH DM insulin - lente 14 3 9 N/A 1500 
20 6 1 3.5 DSH DM insulin-glargine 1 1 5.4 0.07 1287 
21 9 1 5.8 DSH DM insulin - lente 2 3 5.5 N/A >2000 
22 8 1 4.3 
Maine 
Coon DM 
insulin - lente, 
PAS-SAR 21 5 11.1 0.65 >2000 
23 11 2 5.5 DSH 
DM. chronic 
enteropathy 
insulin - glargine, 
PAS-LAR 15 19 8.5 0.40 >2000 
24 8 1 4.6 DSH DM insulin - lente 18 7 11.0 0.61 >2000 
25 14 1 5.4 DSH 
DM, chronic 
enteropathy insulin - lente 0 5 5.0 0.06 1382 
26 10 1 5.4 DSH DM insulin - glargine 3.5 3 5.0 0.05 1567 
27 15 1 11.3 DSH DM insulin - lente 0 21 10.0 N/A 1770 
28 15 1 4.0 BSH DM insulin - lente 0 8 5.2 0.03 >2000 
29 13 1 5.7 DSH DM, CKD 
insulin - glargine, 
PAS-LAR 3 21 5.6 0.08 >2000 
30 13 2 7.7 DSH DM insulin - lente 4 5 6.3 N/A 1304 
31 11 2 5.7 DSH DM insulin - glargine 9 4 7.4 0.17 919 
32 7 2 8.0 DLH DM insulin - lente 7 4 6.2 0.12 1875 
33 10 1 5.9 Bengal DM insulin - lente 5 3 4.8 0.08 1188 
34 9 2 6.6 BSH 
DM, chronic 
enteropathy 
insulin - lente, 
SAMe 5 5 7.2 0.17 1775 
35 12 1 6.7 DSH DM insulin - lente 11 N/R 7.0 0.08 >2000 
36 9 1 4.4 DSH DM insulin - lente 14 6 6.8 0.16 >2000 
37 14 2 4.8 DSH DM 
insulin - PZI, 
PAS-LAR 0.5 13 6.0 N/A 1938 
38 13 2 3.5 DSH 
DM, hypertrophic 
cardiomyopathy insulin - lente 4 4 5.2 0.06 >2000 
39 11 2 3.5 BSH DM insulin - PZI 9 24 5.4 N/A 1210 
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Table 2.Gene expression data and GH, PRL and SSTR2 immunohistochemistry scoring of cats in 
the control and acromegalic groups. 
Contro
l 
Group 
Relative Gene Expression IHC % DAB 
+ive 
IHC 
% 
DAB 
+ive 
Reticuli
n 
staining 
CGA FSHB GH1 LHB PRL TSHB SSTR1 
SSTR
2 
SSTR
5 
DRD
2 AIP 
GHRH
R 
GHS
R ESR1 ESR2 
GPER
1 GH PRL 
SSTR
2 
1 4.235 4.868 3.252 
0.17
5 2.324 3.114 0 0 
0.012
3 0.643 
0.372
8 0.1996 
0.060
3 
0.204
7 
0.454
1 0.6316     
2 5.500 8.317 3.666 
0.30
7 1.502 2.709 0.01 0 
0.060
6 
1.389
1 
0.483
3 0.236 
0.116
5 
0.435
4 0.504 2.2935     
3  
16.91
5 1.553 
1.17
8 1.436 1.886 0.01 0 
0.032
1 
1.372
4 
2.727
9 0.2031 
0.088
6 
0.157
4 
0.573
6 0.5146     
4 2.341 2.536  
0.08
0 1.399 0.844     
0.289
5 0.3056 0 
0.062
1 
0.355
6 0.4907 1.704 3.728 0.346  
5 5.802 4.775 1.173 
0.54
6 2.918 2.524     0 0 0 
0.275
5 
0.816
8 1.9429     
6 4.453 4.742  
0.50
6 2.099 0.952 0.03 0 
0.021
8 
1.312
1 
0.292
3 0.322 
0.233
2 
0.200
5 
0.755
8 1.6494 
75.24
6 4.036 0.000 x 
7 
17.06
0 
20.21
5   7.620 
13.86
6 0.01 
0.002
7 
0.022
4 
1.081
2 
0.357
5 0.2141 
0.175
3 
0.341
4 
0.911
4 0.5207 
62.87
5 4.194 0.864 x 
8 5.708 5.612 3.111 
0.22
6 3.405 3.550 0 0 0 
1.116
8 
0.591
4 0 0 0 
0.096
4 0.5344 
29.30
3 6.927 0.013  
9 2.937 2.857 1.673 
0.44
3 1.965 2.223 0 0 
0.022
3 
1.675
2 0 0 
0.284
5 0 0.21 0.6574 
45.82
6 1.557 0.057 x 
10   3.279              0.525 4.168   
11   5.127    0 
0.013
2 
0.065
3 
0.971
3 0.296 0.3148 
0.288
5 0 
0.350
2 0 7.613 8.105  x 
12       0.01 
0.006
3 
0.067
4 
0.992
8 
0.278
8 0.2802 0.286 0 
0.476
9 0.3031 
10.79
6 0.590 0.001 x 
13                 
42.15
8 
17.88
8  x 
14                 
30.94
6 2.522 0.020 x 
15                 
31.25
3 1.994 0.097  
16                 
39.22
0 0.000   
17                 
40.52
9 
12.87
6 0.003 x 
18                 
16.01
4 
12.11
1  x 
19                 
15.32
4 0.066 0.003 x 
20                 
50.07
5 
12.47
5 0.000 x 
21                 
41.90
6 
18.29
6 7.919 x 
22                 7.965 0.155 0.020  
Acro 
Group  
1 1.604 2.116  
0.03
1 1.598 0.562 0.11 
0.065
1 
0.221
7 
0.741
4 
0.432
6 0.2955 0.12 
0.124
5 
0.218
7 0.3345     
2 1.612 1.585 3.713 
0.05
0 1.840 1.105 0.11 
0.022
3 
0.306
4 
0.858
5 
0.392
8 0.4603 
0.175
9 
0.055
9 
0.464
3 0.6155 
95.61
5 1.256 1.269 x 
3 1.500 0.574  
0.14
7 0.646 0.097 0 0 
0.036
8 
0.167
4 
0.495
8 0.057 
0.020
1 
0.117
7 
0.946
3 1.4239     
4 2.527 2.585   1.978 2.035 0.25 0 0.229 0.947 0.391 0.2925 0.229 0.186 0.605 0.5994 94.66 0.071 0.020  
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5 4 9 9 7 5 2 
5 6.742 7.484 6.750  1.256 1.202 0.03 0 
0.075
5 
1.255
8 
0.652
9 0.3755 
0.236
5 
0.349
1 
0.869
6 0.6269 
88.50
5 0.000 0.008  
6 4.522 5.488  
0.32
5 2.588 2.432 0.01 
0.039
9 
0.088
8 
1.654
4 
0.339
7 0.2428 0.114 0 
0.560
8 1.1691     
7 3.088 3.159 2.927 
0.19
9 2.485 0.878 0.26 
0.063
1 
0.310
1 
1.256
8 
0.291
2 0.4277 
0.337
4 0 0.354 0.7307 
63.75
8 1.060 2.918 x 
8 6.023 6.820  
0.09
6 1.865 3.042 0.03 
0.017
8 
0.117
2 
0.583
4 
0.326
9 0.2541 
0.075
7 
0.185
4 
0.373
6 0.3201 
59.96
5  0.219  
9 1.805 1.300  
0.03
5 2.115 2.332 0.04 0 
0.236
1 
0.743
1 999 999 0.227 
0.010
1 
0.212
6 0.5632 
55.06
4 7.518 0.579 x 
10 3.367 5.492   2.138 0.996 0.19 
0.151
9 
0.112
1 
0.829
7 
0.519
2 0.4121 
0.289
5 
0.030
1 0.474 0.6729 
22.79
1 5.012 
21.54
9 x 
11 4.138 4.230 1.893 
0.23
7 2.537 2.151 0 
0.027
4 
0.054
5 
2.506
4 
0.374
4 0.1422 
0.020
6 
0.042
6 
0.321
7 0.3696 
12.86
9 
20.61
3 1.091 x 
12 3.694 4.490 4.046 
0.11
9 2.402 1.040 0.13 
0.071
6 
0.122
6 
1.143
1 
0.243
7 0.3611 
0.086
7 
0.309
5 
0.668
5 0.2753 
31.14
2 0.688 0.300  
13 
37.37
1 
45.77
9   
11.22
9 
26.89
4 0.09 
0.006
4 
0.156
6 
0.781
5 
0.322
2 0.3158 
0.200
2 0.162 
0.510
8 0.8293 9.999 0.521   
14 4.058 4.561  
0.32
9 2.906 2.251     
1.265
4 0.2225 0 
0.244
8 
0.808
6 1.2097 
39.60
5 1.661  x 
15 5.457 5.663 2.825 
0.76
4 2.254 3.903 0.2 
0.033
1 
0.091
6 
0.922
5 
0.344
7 0.3162 
0.109
4    8.009 0.471   
16 5.550 5.751  
0.25
2 3.401 2.319 0.02 
0.057
6 
0.157
5 
1.013
4 
0.319
2 0.3566 
0.130
7 
0.455
5 
1.018
2 0.7893     
17   7.507    0.01 
0.020
4 
0.096
5 
1.199
5 0 0 
0.103
5 0 
0.583
1 0.5592 
23.46
9 0.039 0.018  
18   
27.79
9              
83.55
7 1.992 0.096 x 
19   3.442              
48.22
8 1.008 0.022  
20   6.247              
56.43
8 0.857 0.166  
21   
15.61
1              
86.84
5 2.619 0.007  
22   0.938              
56.49
2 6.212 0.342 x 
23   6.802              
59.58
3 3.422   
24   
15.61
1              
91.76
1 0.009  x 
25   2.207              
32.14
9 2.877 7.421 x 
26                 
40.87
0 
10.52
4 0.184  
27                 9.727 8.765 0.167 x 
28                 
40.35
3 0.579 0.094 x 
29                 
34.54
5 0.359 0.109 x 
30                 
67.55
5 0.242  x 
31                 
94.01
4 0.000 0.043 x 
32                 
51.61
1 1.128 4.888 x 
33                 
69.54
1 
16.26
1  x 
34                 
55.94
6 3.075  x 
35                 82.17 4.575 0.008 x 
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1 
36                 
56.66
6 0.305 0.016 x 
37                 
15.67
3 
10.44
9   
38                 
26.29
2 4.439  x 
39                 
47.77
1 4.571   
Table 3.Summary of Spearman rank correlation gene expression data in the control group and 
acromegalic groups 
Group Gene Correlate to Gene Spearman's rho P value Adjusted P value 
Control PRL vs TSHβ 0.800 0.010 0.104 
CGA vs PRL 0.810 0.015 0.104 
CGA vs FSHβ 0.786 0.021 0.104 
CGA vs TSHβ 0.714 0.047 0.150 
Acro CGA vs FSHβ 0.979 < 0.001 0.005 
CGA vs TSHβ 0.937 < 0.001 0.005 
FSHβ vs TSHβ 0.930 < 0.001 0.005 
CGA vs PRL 0.615 0.033 0.092 
FSHβ vs PRL 0.615 0.033 0.092 
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